Last $5.43 USD
Change Today -0.08 / -1.45%
Volume 170.7K
ALIM On Other Exchanges
Symbol
Exchange
NASDAQ GM
Frankfurt
As of 8:10 PM 01/30/15 All times are local (Market data is delayed by at least 15 minutes).

alimera sciences inc (ALIM) Snapshot

Open
$5.46
Previous Close
$5.51
Day High
$5.59
Day Low
$5.34
52 Week High
04/1/14 - $8.36
52 Week Low
09/24/14 - $4.58
Market Cap
240.5M
Average Volume 10 Days
161.8K
EPS TTM
$-0.80
Shares Outstanding
44.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ALIMERA SCIENCES INC (ALIM)

alimera sciences inc (ALIM) Related Businessweek News

No Related Businessweek News Found

alimera sciences inc (ALIM) Details

Alimera Sciences, Inc., a biopharmaceutical company, is engaged in the research, development, and commercialization of prescription ophthalmic pharmaceuticals. The company focuses on diseases affecting the back of the eye or retina. The company’s principal product candidate is ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness. Its ILUVIEN is inserted in the back of the patient’s eye to a placement site that uses the eye’s natural fluid dynamics to deliver the corticosteroid fluocinolone acetonide (FAc). The company has completed Phase III pivotal clinical trials for the treatment of DME. It has license agreements with pSivida US, Inc. for the development and sale of ILUVIEN, and a delivery device to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans (other than uveitis) or to treat DME; and Dainippon Sumitomo Pharma Co., Ltd. for the development, manufacture, and marketing of an injectable polymer tube implantable into an eye containing a mixture of a polymer and FAc. Alimera Sciences, Inc. was founded in 2003 and is headquartered in Alpharetta, Georgia.

31 Employees
Last Reported Date: 03/7/14
Founded in 2003

alimera sciences inc (ALIM) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $505.7K
Chief Financial Officer, Chief Operating Offi...
Total Annual Compensation: $352.8K
Chief Scientific Officer and Senior Vice Pres...
Total Annual Compensation: $333.4K
Compensation as of Fiscal Year 2013.

alimera sciences inc (ALIM) Key Developments

Alimera Sciences, Inc.'s ILUVIEN Receives Marketing Authorization in Finland and Luxembourg

Alimera Sciences, Inc. announced that marketing authorization has been granted by the Finnish Medicines Agency in Finland and the Ministry of Health in Luxembourg to ILUVIEN for the treatment of vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies. Approvals in Finland and Luxembourg mark the 14th and 15th European approvals through the Repeat-Use application procedure. ILUVIEN is now approved for marketing in Austria, Belgium, Denmark, France, Germany, Ireland, Italy, the Netherlands, Norway, Portugal, Spain, Sweden, the United Kingdom and the United States, and is commercially available in the United Kingdom, Germany and Portugal. The company expects to begin commercializing ILUVIEN in the U.S. in February 2015. ILUVIEN is pending approval in the Czech Republic and Poland, the two remaining countries in the European Union (EU) included in the Repeat-Use application procedure.

Alimera Sciences, Inc.(NasdaqGM:ALIM) added to NASDAQ Biotechnology Index

Alimera Sciences, Inc. will be added to the NASDAQ Biotechnology Index.

Alimera Sciences' ILUVIEN(R) Receives Marketing Authorization in the Netherlands for the Treatment of Chronic Diabetic Macular Edema

Alimera Sciences, Inc. announced that the Dutch Inspectie voor de Gezondheidszorg (IGZ) has granted marketing authorization in the Netherlands to ILUVIEN(R) for the treatment of vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies. Approval in the Netherlands marks the sixth European approval through the Repeat-Use application procedure and the 14(th) approval worldwide, including the recent U.S. approval for the treatment of DME in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure (IOP). To date, ILUVIEN is now approved for marketing in Austria, Belgium, Denmark, France, Germany, Ireland, Italy, the Netherlands, Norway, Portugal, Spain, Sweden, the United Kingdom and the United States, and is commercially available in the United Kingdom and Germany. ILUVIEN is pending approval in four additional countries in the European Union (EU) included in the Repeat-Use application procedure. These countries are the Czech Republic, Finland, Luxembourg and Poland.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ALIM:US $5.43 USD -0.08

ALIM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ALIM.
View Industry Companies
 

Industry Analysis

ALIM

Industry Average

Valuation ALIM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 29.7x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 17.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALIMERA SCIENCES INC, please visit www.alimerasciences.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.